BIOLOGICTX® DESENSITIZATION DATA SHOWS DECREASED TIME TO TRANSPLANT AND LOW RISK OF AMR POST-TRANSPLANT


Totowa, NJ – September 22, 2016 – BiologicTx® today announced their three year clinical transplant desensitization outcomes that demonstrate that desensitization with IVIg allows patients to reach transplant with a low risk of AMR and excellent allograft function, post-transplant.